People: Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

18 Oct 2019
Change (% chg)

$-0.29 (-1.74%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Struthers, R. Scott 

Dr. R. Scott Struthers is President, Chief Executive Officer, Director of the Company. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies, from 1992 to 1995, to develop and apply computational tools for drug discovery. Dr. Struthers is also a co-founder of the San Diego Entrepreneurs Exchange, a nonprofit organization which he has served on the board of directors of since January 2009. He holds a Ph.D. in physiology and pharmacology from the University of California, San Diego based on the work he performed at the Salk Institute for Biological Studies.

Basic Compensation

Total Annual Compensation, USD 379,200
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 6,322
Fiscal Year Total, USD 385,522

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --